3050-5658

Blood Global Hematology

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 120 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact120 DOIs
2

Deposit reference lists for 13 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact13 DOIs
3

Attach ORCID iDs across 5 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact5 DOIs

DOIs for this ISSN

Showing the top 5 of 120 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 HLA haplotype frequency analysis reveals large patient benef… (10.1016/j.bglo.2025.100028)
Abstract
15.05 3
2 Development of disease-specific growth curves from Kenyan ch… (10.1016/j.bglo.2025.100031)
Abstract
11.93 2
3 Hematologic cancers in the SAARC region: current burden in 2… (10.1016/j.bglo.2025.100036)
Abstract
11.93 2
4 Hydroxyurea therapy in sickle cell disease: evaluating healt… (10.1016/j.bglo.2025.100040)
Abstract
11.93 2
5 CAR-T in resource-limited regions (10.1016/j.bglo.2025.100051)
Abstract
11.93 2
6 Molecular diagnosis of hemophilia in the era of advanced gen… (10.1016/j.bglo.2026.100089)
Abstract
11.93 2
7 Venetoclax for unfit AML: real-world outcomes of standard an… (10.1016/j.bglo.2026.100097)
Abstract
11.93 2
8 Hydroxyurea to decrease stroke risk in children with sickle… (10.1016/j.bglo.2025.100001)
Abstract
7.53 1
9 Comparing the distribution of Hodgkin lymphoma subtypes and… (10.1016/j.bglo.2025.100002)
Abstract
7.53 1
10 Latin America and evolving oncotherapeutics using CAR T cell… (10.1016/j.bglo.2025.100007)
Abstract
7.53 1
11 Maternal death and postpartum hemorrhage in sub-Saharan Afri… (10.1016/j.bglo.2025.100008)
Abstract
7.53 1
12 Introduction of treatment for children with acute lymphoblas… (10.1016/j.bglo.2025.100011)
Abstract
7.53 1
13 Integration of NGS and CNV analysis in prognostic evaluation… (10.1016/j.bglo.2025.100014)
Abstract
7.53 1
14 Erythrocyte alloimmunization in children with sickle cell an… (10.1016/j.bglo.2025.100016)
Abstract
7.53 1
15 Racial disparities in multiple myeloma (10.1016/j.bglo.2025.100017)
Abstract
7.53 1
16 Real-world analysis of patients with CLL treated with ibruti… (10.1016/j.bglo.2025.100019)
Abstract
7.53 1
17 Max Access Solutions: an innovative model to bring life-savi… (10.1016/j.bglo.2025.100023)
Abstract
7.53 1
18 Circulating plasma EBV DNA: a potential tool to facilitate d… (10.1016/j.bglo.2025.100025)
Abstract
7.53 1
19 Asian-type DEL among D-negative patients and donors in Malay… (10.1016/j.bglo.2025.100029)
Abstract
7.53 1
20 Clinical outcomes of patients with chronic myeloid leukemia… (10.1016/j.bglo.2025.100035)
Abstract
7.53 1
21 Tracing the origin of sickle cell disease back to 50 000 yea… (10.1016/j.bglo.2025.100041)
Abstract
7.53 1
22 Outpatient low-dose venetoclax-azacitidine vs intensive ther… (10.1016/j.bglo.2025.100045)
Abstract
7.53 1
23 HLA-B leader mismatch predicts increased GVHD risk in haploi… (10.1016/j.bglo.2025.100048)
Abstract
7.53 1
24 Bridging the gap: AML induction in low-resource settings (10.1016/j.bglo.2025.100049)
Abstract
7.53 1
25 Characteristics of 66 000 consecutive blood donations in the… (10.1016/j.bglo.2026.100075)
Abstract
7.53 1
26 Response rate and survival of patients with chronic-phase ch… (10.1016/j.bglo.2026.100083)
Abstract
7.53 1
27 The role of outer setting health system factors in the use o… (10.1016/j.bglo.2026.100091)
Abstract
7.53 1
28 High early mortality among Ugandan children with sickle cell… (10.1016/j.bglo.2026.100093)
Abstract
7.53 1
29 Real-world insights into acquired aplastic anemia: the Latin… (10.1016/j.bglo.2026.100094)
Abstract
7.53 1
30 Field evaluation of the Sickle Confirm point-of-care test fo… (10.1016/j.bglo.2026.100096)
Abstract
7.53 1
31 Pilot of the International Hemoglobinopathy Research Network… (10.1016/j.bglo.2026.100098)
Abstract
7.53 1
32 Clinical practice recommendations for myelofibrosis manageme… (10.1016/j.bglo.2025.100003)
Abstract
0.00 0
33 Substantially improved survival for intermediate-risk AML: a… (10.1016/j.bglo.2025.100004)
Abstract
0.00 0
34 Allogeneic HSCT in children with relapsed/refractory acute l… (10.1016/j.bglo.2025.100005)
Abstract
0.00 0
35 Impact of socioeconomic status on acute myeloid leukemia out… (10.1016/j.bglo.2025.100006)
Abstract
0.00 0
36 Global blood and marrow transplantation training for interna… (10.1016/j.bglo.2025.100009)
Abstract
0.00 0
37 Impact of resource availability on outcomes of diffuse large… (10.1016/j.bglo.2025.100010)
Abstract
0.00 0
38 Report on management approaches and treatment results in chr… (10.1016/j.bglo.2025.100012)
Abstract
0.00 0
39 Welcome to Blood Global Hematology (10.1016/j.bglo.2025.100013)
Abstract References
0.00 0
40 Experience in the diagnosis and treatment of AL amyloidosis… (10.1016/j.bglo.2025.100015)
Abstract
0.00 0
41 Twenty core entrustable professional activities for hematolo… (10.1016/j.bglo.2025.100018)
Abstract
0.00 0
42 Immunogenomic profiles of HIV-associated classic Hodgkin lym… (10.1016/j.bglo.2025.100020)
Abstract
0.00 0
43 Hodgkin lymphoma treatment patterns and outcome disparities… (10.1016/j.bglo.2025.100021)
Abstract
0.00 0
44 First Latin America description of myelodysplastic syndrome… (10.1016/j.bglo.2025.100022)
Abstract
0.00 0
45 Real-world outcomes of multiple myeloma in a resource-constr… (10.1016/j.bglo.2025.100024)
Abstract
0.00 0
46 Experience of AL in Latin America (10.1016/j.bglo.2025.100026)
Abstract
0.00 0
47 Real-world ibrutinib in CLL: efficacy, tolerability, access (10.1016/j.bglo.2025.100027)
Abstract
0.00 0
48 Real-world outcome of acute promyelocytic leukemia treatment… (10.1016/j.bglo.2025.100030)
Abstract
0.00 0
49 Neurocognitive functioning of patients with sickle cell dise… (10.1016/j.bglo.2025.100032)
Abstract
0.00 0
50 Closing gaps in transplant access (10.1016/j.bglo.2025.100033)
Abstract
0.00 0